Register For Our Mailing List

Register to receive our free weekly newsletter including editorials.

Home / 322

Four companies riding the healthcare boom

Healthcare is a sector with plenty of tailwinds. This article identifies four companies that stand to benefit from demographic and economic trends while also providing a social good.

Three major trends to follow

Three major trends are underway that are positive for companies operating in the healthcare sector:

  1. The ageing of the population means more money is being spent more on healthcare.
  2. Rising living standards cause people to preference healthcare spending over other consumer goods.
  3. Technology improvements create additional opportunities.

Along with these trends, healthcare is a sector that aligns well with our core beliefs as an ethical funds management business. Healthcare technologies have made phenomemal advances that enable people to live longer, healthier lives. But that doesn’t mean we will invest in any healthcare company. Alongside our disciplined investment criteria we are also guided by the Australian Ethical Charter. For example, we have strict restrictions when it comes to medical testing using animals and we require biotech companies to conduct their research responsibly.

These ethical considerations and economic tailwinds combine to make healthcare a significant part of our Australian Shares Fund at approximately 15-20%. We try not to pay too much attention to macro factors or the index when we think about stocks, and we invest in smaller sized companies which often have a longer pathway of growth.

The healthcare companies we invest in are involved in a range of activities including pharmacy, insurance, radiology, medical devices and different sorts of pharmaceuticals.

Here are four examples of healthcare stocks we hold in our Australian Shares Fund.

Fisher & Paykel Healthcare

Fisher & Paykel is generally associated with household appliances, but it also has a healthcare division which was spun out in 2001. We’ve been invested in Fisher & Paykel Healthcare for around 10 years and it’s a great example of a company that’s managed to reinvent itself several times.

The big discovery for Fisher & Paykel Healthcare was that humidifying air used for breathing during intensive care (ie, emergency situations) improves patient outcomes. They’ve managed to take that core technology into non-invasive ventilation, sleep apnea and some surgical procedures. Their big growth focus currently is re-shaping the delivery of oxygen therapy with their ‘Nasal High Flow’ solution which is used in the care of infants and children.

These products have delivered handsome rewards to investors who have been attracted to Fisher & Paykel’s high-margin recurring consumable earnings. As the stock has appreciated we’ve adjusted our position size down, but they still appear reasonably valued against some higher rated sector peers.

Healius

Healius was formerly known as Primary Health Care. It has been a long-term share market underperformer in which we have recently accumulated a position. Their core diagnostic and medical centre assets are potentially strategically valuable despite their operational struggles, and there has been public speculation about corporate activity in the stock. More importantly, we believe earnings have stabilised following a period of decline and the regulatory environment is benign. The company’s balance sheet has improved following a capital raising and the accounting practices of the company have become more conservative through time. Valuation metrics look appealing in the context of the sector.

Capitol Health

Capitol Health is a diagnostic imaging business. This was more of an opportunistic investment for us because it was a company going through quite a lot of problems when we first invested. Like many companies that make lots of acquisitions, it ran into problems after it grew too quickly and took on too much debt. We participated in the recapitalisation of the business at a share price of 14 cents as part of the company’s plan to take out costs and reduce debt.

That strategy played out well with a few ups and downs along the way. The company’s balance sheet received a major boost with the sale of its NSW assets at an attractive price. Capitol Health remains in our portfolio and trades at a reasonable earnings multiple. It’s also within an industry that may present further opportunities for consolidation down the track.

Cyclopharm

Finally, Cyclopharm is a smaller emerging healthcare technology player that represents a small position in our portfolio. It’s an early-stage company that actually has revenue and pays a dividend, which is somewhat unique for the sector.

Cyclopharm has a lung-imaging solution for patients who are suspected of having pulmonary embolism but who are unable to have CT scans. The company has developed a gas that’s inhaled in a process called ventilation-perfusion. And they’ve actually commercialised this technology already. It’s distributed in 55 countries and has been written up in guidelines as a highly-efficacious technology in that space.

The real opportunity here is that the major market in the world where this technology has yet to be approved is the US. It’s currently going through a clinical trial in the US which has taken longer than expected. But this trial is once more advancing and we’re quite excited about the opportunity it represents for us as investors and for the patients who stand to benefit.

 

Mike Murray is an Analyst at Australian Ethical, a sponsor of Cuffelinks. This article is general information and does not consider the circumstances of any investor.

For more articles and papers from Australian Ethical, including Graham Hand's interview with AE's Managing Director, Phil Vernon, please click here.

 

banner

Most viewed in recent weeks

Why the $5.4 trillion wealth transfer is a generational tragedy

The intergenerational wealth transfer, largely driven by a housing boom, exacerbates economic inequality, stifles productivity, and impedes social mobility. Solutions lie in addressing the housing problem, not taxing wealth.

The 2025 Australian Federal election – implications for investors

With an election due by 17 May, we are effectively in campaign mode with the Government announcing numerous spending promises since January and the Coalition often matching them. Here's what the election means for investors.

Finding the best income-yielding assets

With fixed term deposit rates declining and bank hybrids being phased out, what are the best options for investors seeking income? This goes through the choices, and the opportunities and risks involved.

What history reveals about market corrections and crashes

The S&P 500's recent correction raises concerns about a bear market. History shows corrections are driven by high rates, unemployment, or global shocks, and that there's reason for optimism for nervous investors today. 

Howard Marks: the investing game has changed

The famed investor says the rapid switch from globalisation to trade wars is the biggest upheaval in the investing environment since World War Two. And a new world requires a different investment approach.

Welcome to Firstlinks Edition 605 with weekend update

Trump's tariffs and China's retaliatory strike have sent the Nasdaq into a bear market with the S&P 500 not far behind. What are the implications for the economy and markets, and what should investors do now? 

  • 3 April 2025

Latest Updates

Investment strategies

4 ways to take advantage of the market turmoil

Every crisis throws up opportunities. Here are ideas to capitalise on this one, including ‘overbalancing’ your portfolio in stocks, buying heavily discounted LICs, and cherry picking bombed out sectors like oil and gas.

Shares

Why the ASX needs dual-class shares

The ASX is exploring the introduction of dual class share structures for listed companies. Opposition is building to the plan but the ASX should ignore the naysayers and bring Australia into line with its global peers.

The state of women's wealth in Australia

New research shows the average Australian woman has $428,000 in net wealth, 40% less than the average man. This takes a deep dive into what the gender wealth gap looks like across different life stages.

Investing

The two most dangerous words in investing

Market extremes are where the biggest investment risks and opportunities lie. While events like this are usually only obvious in hindsight, learning to watch out for these two words can alert you to them in real time.

Shares

Investing in the backbone of the digital age

Semiconductors are used to make microchips and are essential to a vast range of technology and devices. This looks at what’s driving demand for chips, how the industry is evolving, and favoured stocks to play the theme.

Gold

Why gold’s record highs in 2025 differ from prior peaks

Gold prices hit new recent highs, driven by a stronger euro, tariff concerns, and steady ETF buying – all while the precious metal’s fundamental backdrop remains solid amid a shifting global economic landscape.

Now might be the best time to switch out of bank hybrids

In this interview, Schroders' Helen Mason discusses investing in corporate and financial credit securities, market impacts of tariffs, opportunities for cash investments, and views on tier two and hybrid bonds.

Sponsors

Alliances

© 2025 Morningstar, Inc. All rights reserved.

Disclaimer
The data, research and opinions provided here are for information purposes; are not an offer to buy or sell a security; and are not warranted to be correct, complete or accurate. Morningstar, its affiliates, and third-party content providers are not responsible for any investment decisions, damages or losses resulting from, or related to, the data and analyses or their use. To the extent any content is general advice, it has been prepared for clients of Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892), without reference to your financial objectives, situation or needs. For more information refer to our Financial Services Guide. You should consider the advice in light of these matters and if applicable, the relevant Product Disclosure Statement before making any decision to invest. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your situation, contact a professional financial adviser. Articles are current as at date of publication.
This website contains information and opinions provided by third parties. Inclusion of this information does not necessarily represent Morningstar’s positions, strategies or opinions and should not be considered an endorsement by Morningstar.